BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TransForm Pharmaceuticals, Inc. Announces Agreement With Eli Lilly and Company (LLY); Collaboration To Improve Preclinical Formulation Screening


10/19/2005 5:11:27 PM

TransForm Pharmaceuticals, Inc. (TransForm) today announced that it has entered into a new agreement with Eli Lilly and Company (NYSE:LLY) to apply TransForm's capabilities to develop a robust method of identifying optimal formulations for preclinical drug candidates. Under the collaboration, TransForm's scientists will conduct over 10,000 formulation experiments to develop an extensive data set of quantitative measurements that will identify the optimal formulations for preclinical candidates. Using proprietary informatics capabilities, TransForm will develop a novel suite of tools that is intended to allow Lilly to improve the speed and success rate of its preclinical compounds by moving them into in vivo toxicology studies earlier and with more reliable formulations. TransForm will retain rights to use the new tools to improve its own proprietary pipeline of product candidates. Financial terms of the agreement were not disclosed and the work will start immediately.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES